AlphaTON Capital (ATON)
NASDAQ:ATON
Top Page
AlphaTON Capital
(NASDAQ:ATON)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.28
▼(-53.77% Downside)
Action:UpgradedDate:03/24/26
The score is driven primarily by very weak financial performance (no reported revenue, persistent losses, ongoing cash burn, and equity deterioration to slightly negative). Technicals add additional pressure with a broadly bearish trend (price below key moving averages and negative MACD), while valuation metrics provide limited support due to a negative P/E and no indicated dividend yield.
Positive Factors
Low leverage / conservative capital structure
Very low debt reduces fixed interest obligations and preserves financial flexibility, giving management runway to fund strategic pivots or absorb short-term losses without immediate refinancing. This durable capital structure helps mitigate funding risk while the company pursues new revenue streams.
Negative Factors
No reported revenue and persistent losses
A business without an established revenue base faces structural viability risk: management must transition from asset or pilot activities to sustained, fee-generating operations. Persistent losses erode equity and make profitable scale and margin sustainability harder without durable client fee streams.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / conservative capital structure
Very low debt reduces fixed interest obligations and preserves financial flexibility, giving management runway to fund strategic pivots or absorb short-term losses without immediate refinancing. This durable capital structure helps mitigate funding risk while the company pursues new revenue streams.
Read all positive factors
AlphaTON Capital (ATON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.02M
Dividend YieldN/A
Average Volume (3M)1.13M
Price to Earnings (P/E)―
Beta (1Y)2.15
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees4
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,434,587
10 Day Avg. Volume2,947,603
30 Day Avg. Volume1,125,115
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-88.97
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.03
Forecast
1Y Price Target
$2.00Price Target Upside227.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AlphaTON Capital Business Overview & Revenue Model
Company Description
AlphaTON Capital Corp. is the rebranded entity formerly known as Portage Biotech Inc., a clinical-stage immuno-oncology company transitioning into a digital asset treasury model focused on accumulating and staking Toncoin (TON). AlphaTON intends t...
How the Company Makes Money
AlphaTON Capital (ATON) generates revenue primarily through management fees and performance fees associated with its investment products and services. Management fees are charged as a percentage of the assets under management (AUM), providing a co...
AlphaTON Capital Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -35.00K | -54.00K | -1.00K | 0.00 | 0.00 |
| EBITDA | -16.37M | -6.74M | -18.20M | -122.25M | -14.77M | -14.71M |
| Net Income | -19.69M | -6.77M | -75.34M | -104.61M | -16.87M | -15.83M |
Balance Sheet | ||||||
| Total Assets | 30.59M | 2.23M | 7.78M | 99.13M | 194.66M | 174.86M |
| Cash, Cash Equivalents and Short-Term Investments | 183.00K | 1.67M | 5.03M | 10.54M | 23.35M | 2.77M |
| Total Debt | 0.00 | 0.00 | 47.00K | 0.00 | 0.00 | 150.00K |
| Total Liabilities | 21.70M | 3.05M | 4.45M | 23.73M | 29.23M | 27.26M |
| Stockholders Equity | 9.59M | -123.00K | 4.02M | 76.05M | 121.20M | 101.45M |
Cash Flow | ||||||
| Free Cash Flow | -3.65M | -5.46M | -14.30M | -12.08M | -6.76M | -3.28M |
| Operating Cash Flow | -3.65M | -5.46M | -14.30M | -12.07M | -6.76M | -4.28M |
| Investing Cash Flow | -50.00K | 0.00 | 2.81M | -617.00K | 0.00 | -860.00K |
| Financing Cash Flow | 2.12M | 2.10M | 5.97M | -117.00K | 27.35M | 4.76M |
AlphaTON Capital Technical Analysis
Negative
0.61
Price Trends
0.49
Negative
1.22
Negative
3.81
Negative
Market Momentum
-0.05
Negative
30.66
Neutral
14.84
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATON, the sentiment is Negative. The current price of 0.61 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.49, and below the 200-day MA of 3.81, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 30.66 is Neutral, neither overbought nor oversold. The STOCH value of 14.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATON.
AlphaTON Capital Risk Analysis
AlphaTON Capital disclosed 28 risk factors in its most recent earnings report. AlphaTON Capital reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
We rely on information technology and security systems and any damage, interruption or compromise of our information technology and security systems or data could disrupt and harm our business. Q1, 2023
2.
Any actual or perceived failure by us to comply with government or other obligations related to privacy or data protection could adversely affect our business. Q1, 2023
AlphaTON Capital Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
51 Neutral | $13.94M | -1.29 | -107.58% | ― | ― | 83.95% | |
46 Neutral | $5.96M | -2.52 | -229.48% | ― | ― | 71.57% | |
43 Neutral | $11.07M | -0.59 | -248.91% | ― | ― | 79.31% | |
41 Neutral | $7.02M | -0.33 | -925.11% | ― | ― | ― | |
41 Neutral | $7.01M | -0.33 | ― | ― | ― | ― | |
41 Neutral | $8.17M | -0.31 | -97.58% | ― | -46.88% | 34.83% |
* Financial Sector Average
ATON
AlphaTON Capital
0.30
-8.95
-96.77%
CANF
Can-Fite BioPharma
3.01
-26.59
-89.83%
PHIO
Phio Pharmaceuticals
1.20
-0.10
-7.69%
CLRB
Cellectar Biosciences
2.61
-6.85
-72.41%
MTVA
MetaVia
1.17
-15.77
-93.09%
BOLT
Bolt Biotherapeutics
4.25
-3.75
-46.88%
AlphaTON Capital Corporate Events
AlphaTON Capital Moves to Take Control of GaMee in $3.5 Million Gaming Ad Deal
Mar 20, 2026
On March 19, 2026, AlphaTON Capital Corp agreed to acquire a 60% controlling stake in Ga Mee Global Limited from Animoca Brands, in a $3.5 million upfront deal split between cash and equity, alongside a commitment to purchase $2 million of GaMee t...
AlphaTON Capital Faces Nasdaq Bid-Price Deficiency, Given Until August 31 to Regain Compliance
Mar 2, 2026
On March 2, 2026, AlphaTON Capital Corp disclosed that it received a deficiency notice from the Nasdaq Listing Qualifications Department after its common stock traded below the $1.00 minimum bid price for 30 consecutive business days. The notice d...
AlphaTON Capital Leases 504 Nvidia B200 GPUs to Scale Confidential AI Infrastructure in Canada
Feb 18, 2026
On February 17, 2026, AlphaTON Capital announced it had signed and closed a $30 million AI compute infrastructure lease, adding 504 Nvidia Blackwell B200 GPUs to its Canadian deployment in a move that management says should deliver an estimated mi...
AlphaTON Capital Signs Option Deal to Sell iOx Therapeutics to Immunova While Retaining Biotech Upside
Feb 18, 2026
On February 17, 2026, AlphaTON Capital Corp. reported that it had executed a binding call option agreement granting Immunova, LLC, or an affiliate, the right to acquire iOx Therapeutics Limited, its wholly owned biotech subsidiary focused on lipos...
AlphaTON Capital Launches $400 Million ATM Share Offering to Fund Cocoon AI and Strategic Deals
Feb 17, 2026
On February 17, 2026, AlphaTON Capital Corp. entered into an at-the-market offering agreement with H.C. Wainwright Co. that allows the company to sell up to $400 million of its ordinary shares from time to time on Nasdaq and other U.S. trading ve...
AlphaTON Capital Unwinds 2025 Share Exchange With Compedica
Feb 10, 2026
On February 6, 2026, AlphaTON Capital Corp entered into an agreement with Compedica Holdings Limited to terminate and rescind their June 5, 2025 Subscription Agreement, under which AlphaTON had issued 625,000 of its ordinary shares at $8.00 per sh...
AlphaTON Capital Announces Board Resignation and New Director Appointment
Feb 6, 2026
On February 5, 2026, director Steven Mintz informed AlphaTON Capital Corp of his decision to resign from the company’s board of directors, with the resignation becoming effective on February 6, 2026. On the same day, February 6, 2026, the bo...
AlphaTON Capital Raises $44 Million and Begins Generating AI Infrastructure Revenue for Telegram Cocoon AI
Jan 28, 2026
On January 28, 2026, AlphaTON Capital reported that it has raised a net $44 million in capital, deployed revenue-generating AI infrastructure for Telegram’s Cocoon AI network, and is broadening its role as a foundational provider of confiden...
AlphaTON Capital Raises $15 Million in Registered Direct Offering to Scale Cocoon AI
Jan 15, 2026
On January 13, 2026, AlphaTON Capital Corp entered into a securities purchase agreement for a registered direct offering of 15 million ordinary shares or pre-funded warrants at $1.00 per security, with closing completed on January 14, 2026, genera...
AlphaTON Capital Files Q2 2025 Interim Results, Revealing Major Digital Asset-Driven Balance Sheet Expansion
Jan 13, 2026
On January 12, 2026, AlphaTON Capital Corp filed a Form 6-K for January 2026, furnishing unaudited condensed consolidated interim financial statements and management’s discussion and analysis for the three and six months ended September 30, ...
AlphaTON Capital Ends At-The-Market Share Offering Agreement With Chardan
Jan 9, 2026
On November 25, 2025, AlphaTON Capital Corp. filed a prospectus supplement with the U.S. Securities and Exchange Commission to offer and sell up to approximately $15.3 million of its ordinary shares under an at-the-market (ATM) offering agreement ...
AlphaTON Capital Partially Unwinds September 2025 Private Placement After Investor Exercises Put Option
Dec 31, 2025
On December 8, 2025, AlphaTON Capital Corp was required to honor a previously disclosed put option granted to certain investors in connection with its September 25, 2025 private placement financing. Under a side letter agreement, one investor exer...
AlphaTON Capital Unwinds TON Treasury Deal With DWF in $15 Million Settlement
Dec 31, 2025
On December 30, 2025, AlphaTON Capital Corp entered into a Settlement Agreement and Release with DWF MaaS Limited to resolve disputes over rights and obligations arising from an August 25, 2025 Treasury Management Agreement under which DWF had bee...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.